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Summary
Objective: Analyze the effect on survival of secondary cytoreduction surgery (SCS) in treatment of first recurrence platinum­sensitive
epithelial ovarian cancer (REOC). Methods: Retrospective analysis of patients with first REOC who had platinum time­free interval
(TFIp) > 6 months and were treated either with SCS followed by chemotherapy or chemotherapy only (CT). Clinical data such as
patient’s performance status and number of sites with metastases were specifically assessed. The primary endpoint was overall survival
(OS). Results: Seventy­one patients were treated either by SCS (n = 37) or CT (n = 34). Complete resection after SCS was achieved in
89% of patients. After a median follow­up of 51.2 months, median OS, and progression­free survival (PFS) were 68.2 and 21.6 months,
respectively, for the whole series of the SCS patients had better survival and disease progression survival than the CT only patients (HR:
0.33, 95%CI: 0.17­0.6; p= 0.001) and (HR: 0.28, 95%CI: 0.15­0.5; p= 0.001), respectively. TFIp < 12 months and multiple metastases
were most important prognostic factors for risk of death (HR: 7.7 and 6.2, respectively) and recurrence (HR: 5.8 and 3.8, respectively).
Probability to undergo successful SCS is related to oligometastatic disease and no residual disease after first surgery (OR: 30.0 and 5.9,
respectively). Conclusions: In women with REOC oligometastatic disease and no residual disease at first surgery are associated with
successful SCS. In these patients oligometastatic disease and long platinum TFI are associated with improved probability of survival.
Key words: Ovarian cancer; Recurrence; Secondary cytoreductive surgery; Survival; Morbidity.
Introduction
Current standard treatment for recurrent epithelial ovar­
ian cancer (REOC) is principally chemotherapy (CT); based
on a combination of platinum­containing drugs for those
considered platinum­sensitive [1, 2]. Secondary cytoreduc­
tive surgery (SCS) has also been considered in patients with
progression free interval (PFI)≥ 6 months and limited dis­
ease volume, with a survival benefit associated with com­
plete cytoreduction and optimal post­operative chemother­
apy.
As with all elective procedures, the benefits of SCS need
to be weighed against the risks of morbidity and mortality,
so there is need for the identification of factors that will al­
low us to select the best candidates for SCS [3­7]. Various
predictive scores have been developed to accomplish this
goal. The AGO score has been the most used worldwide
so far [4]. Nevertheless, a high false negative rate of some
scores is of concern and additional prognostic factors have
been included in the models to try to overcome this limita­
tion [8­14].
Few studies have directly compared the outcomes of
REOC patients who underwent SCS to those treated with
CT alone. They found a clear benefit of SCS over CT alone,
but there are concerns that this benefit may reflect selection
bias rather than superiority of SCS [15­18].
Currently, two prospective multicenter randomized sur­
gical trials in platinum­sensitive REOC have been accom­
plished, the DESKTOP III [19] and GOG 213 [20], with
overall survival as the primary end point. The final results
of GOG 213 showed that, despite a 67% rate of complete
resection in the surgery arm, SCS did not result in longer
overall survival than chemotherapy alone [21]. The DESK­
TOP study results presented at the 2020 American Society
of Clinical Oncology meeting showed a clear advantage of
overall survival for surgically treated patients. In 74.2% of
them a macroscopic complete resection was achieved and
overall survival in this subgroup was significantly better
compared with patients in the no surgery arm [19].
Objectives
The aim of this study is to identify factors associated
with successful SCS. We also aim to compare the outcome
of patients who are selected to undergo SCS to those who
are treated with chemotherapy only.
524 Silvia Ortega, José Angel Mínguez, José Manuel Aramendía...
Table 1. — General characteristics of the patients
All (n = 71) S+CT (n = 37) CT (n = 34) p
Age in years, mean (range) 59 (24­80) 55.4 (24­80) 62.8 (24­79) 0.01
BMI, mean (range) 26 (18­38) 26.4 (18­37) 25.9 (19­38) 0.6
PFI, mean (range) 33 (6­141) 37.2 (6­141) 26.0 (8­93) 0.1
TFIp, mean (range) 27 (6­129) 33.0 (6­129) 21.3 (7­87) 0.09
No RD 1st surgery, N (%) 49 (100) 31 (63.3) 18 (36.7) 0.009
FIGO stage
I­II 16 (22.5) 16 (100) 0 0.001
III­IV 55 (77.5) 21 (38.2) 34 (61.8) 0.001
ASA (%) 0.98
1­2 63 (88.7) 33 (89.2) 30 (88.2)
>3 8 (11.3) 4 (10.8) 4 (11.8)
ECOG 0.7
0­1 64 (90) 34 (91.9) 30 (88.2)
≥ 2 7 (10) 3 (8.1) 4 (11.8)
Histology (of recurrence) n (%) 0.06
Serous 57 (80.3) 25 (43.9) 32 (56.1)
High grade 41 (73.2) 15 (60.0) 26( 83.9)
Low grade 15 (26.8) 10 (40.0) 5 (16.1)
Endometrioid 3 (4.2) 2 1 NA
Mucinous 3 (4.2) 2 1 NA
Clear Cell 6 (8.5) 6 0 NA
Mixed/Other 2 (2.8) 2 0 NA
Grade n (%) 0.08
1 10 (14.3) 8 (21.6) 2 (6.1)
2 13 (18.6) 8 (21.6) 5 (15.2)
3 47 (67.1) 21 (56.8) 26 (78.8)
Diagnostic Tool 0.77
CT­scan ± Ca­125 45 (63.3) 23 (62.2) 2 (5.4)
PET­CT scan ± Ca­125 24 (33.8) 12 (34.4) 12 (35.3)
Biopsy 2 (2.8) 2 (5.4) 0
Ascites (at diagnosis) 0.2
Yes 5 (7.2) 1 (2.7) 4 (12.5)
No 66 (92.8) 36 (97.3) 30 (87.5)
CA­125(log) mean(range) 1.8­(0.6­3.5) 1.6 (0.6­2.7) 1.9 (0.6­3.6) 0.008
CT at recurrence, n (%) 0.1
Carboplatin/paclitaxel 42 (59.2) 26 (70.3) 16 (47.1)
Carboplatin/paclitaxel 11 (15.5) 6 (16.2) 5 (14.7)
pegylated doxorubicin 12 (16.9) 3 (8.1) 9 (26.4)
gemcitabine 6 (8.5) 2 (5.4) 4 (11.8)
Others*** 29 (40.8) 11 (37.9) 18 (62.1) 0.05
Bevacizumab Number of Cycles, median(range) 5.9 (2­12) 6.0 ( 2­12) 5.9 (3­8) 0.66
S: surgery. CT: chemotherapy. PFI: Progression­free interval. TFIp: Platinum treatment­free interval.
Methods
From January 2000 to December 2014, 180 recurrent
ovarian cancer patients came to our institution seeking treat­
ment. After Institutional Review Board approval was ob­
tained (UNAV2018.007), seventy­one (39%) patients who
were platinum sensitive (> 6 months from the last cycle of
CT to progression) and had good performance status (ASA
≤ 3/ECOG< 2) andwho underwent SCS or CT alone were
considered as eligible for this study.
According to our institution’s criteria derived from
studies published during the late nineteen­nineties [5],
candidates for surgery had to be oligometastatic (< 4
metastatic lesions), either within the abdomen (intra­ or
retroperitoneally) or out of the abdomen (inguinal recur­
rence, cardiophrenic, supraclavicular, pulmonary or hep­
atic, among others) if risk/benefit was considered propor­
tionate. Whereas candidates for CT alone were those who
had > 4 metastatic sites or the risk for surgery was consid­
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Table 2. — Characteristics of the recurrences
All (n = 71) S+CT (n = 37) CT (n = 34) p
Site of Recurrence* n (%) n (%) n (%)
Peritoneal 0.014
Abdomen 17 (23.9) 7 (41.2) 10 (58.8)
Pelvis 19 (26.7) 16 (84.2) 3 (15.8)
Lymph nodes NA
Abdomen 9 (12.7) 4 (44.4) 5 (55.6)
Parenchymal∗∗ 8 (11.3) 6 (75.0) 2 (25.0) 0.73
Mixed 16 (22.5) 4 (25.0) 12 (75.0) 0.01
Number of metastases 0.0001
Single 22 (31.0) 21 (56.8) 1 (2.9)
Isolated (≤ 4) 14 (19.7) 10 (27.0) 4 (11.8)
Multiple 35 (49.3) 6 (16.2) 29 (85.3)
*Total number of each site with metastasis, **Liver, Spleen, Pleural, Lung, C+CT
= chemotherapy and surgery, CT = chemotherapy.
Figure 1. — Overall survival (A) and progression free survival (B) according to treatment (Secondary cytoreduction surgery and
chemotherapy versus chemotherapy only).
ered as disproportionate.
Age, degree of tumor cytoreduction at the time of pri­
mary surgery or the presence of ascites on computerized
tomography (CT­scan) were not exclusion criteria for be­
ing considered as a surgical candidate. In addition, a la­
paroscopic evaluation of intraperitoneal disease was recom­
mended to assess the feasibility of complete resection when
suspicion of multiple metastases or the appropriateness of
any extraordinary surgical approach.
Patients who were not fit for surgical resection un­
derwent CT alone, while those who completed surgery
were treated with adjuvant CT after surgery. Adjuvant or
CT alone consisted of a combination of platinum deriva­
tives and taxanes, doxorubicin, gemcitabine, etoposide,
and topotecan. Poly (ADP­ribose) polymerase (PARP) in­
hibitors were rarely given. Bevacizumab (BV) was admin­
istered according to a case­by­case decision. No informa­
tion was recorded about the number of patients who refused
any treatment.
Follow­up of at least two years since the end of either
treatment was requested. Follow­up evaluation consisted
of history and physical examination, routine biochemical
and hematologic laboratory assessment including CA­125,
CT­scan or positron emission tomography (PET­CT scan).
Diagnosis of recurrence was considered as true when both
images and CA­125 were compatible with disease, and very
rarely a confirmation biopsy was required.
Recurrent disease was classified based on the follow­
ing anatomic sites: parenchymal disease (involvement of
liver, spleen, and lung metastases); peritoneal (involve­
ment of the peritoneum (abdomen or pelvis) and/or colon­
sigmoid); nodal disease (involvement of lymph, either ab­
dominal (pelvic, para­aortic) or extra­abdominal (groin,
latero­cervical, mediastinum)); and mixed (combination
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Table 3. — Surgical procedures performed in the surgical
group






Small inestine 5 (13.5)
Large intestine 4 (10.8)
Sigmoidectomy 13 (18.3)









Abdominal wall 3 (8.1)
Complex Retroperitoneal 2 (5.4)




Diaphragm (peritoneal stripping) 2 (5.4)
Radical 19 (51.4)
Surgery Time in hours [mean (range)] 3.6 (1­9.7)
*Supraclavicular (1), Inguinal (1), Mediastinal (2).
of different sites). Extent of disease was classified as
oligometastatic (≤ 4 lesions) and multiple.
Overall survival (OS) was measured in months from the
date of primary surgery or the beginning of chemotherapy
to the time of death or last follow­up visit. Progression­free
survival (PFS) was measured from the date of surgery or
the beginning of CT to the time of failure or death.
Complications occurring during the first 30 days after
surgery were captured and graded according to the Clavien­
Dindo scale [22].
All data were extracted by reviewing patients’ medical
and surgical records.
Statistical analysis was performed with SPSS for Win­
dows 20 software. Continuous data are presented as mean
with standard deviation or range or median with interquar­
tile range (IQR). Categorical data are presented as the num­
ber of cases and percentages. Categorical data were com­
pared using two­tailed Fisher’s exact test where appro­
priate. Kruskal­Wallis test was used for comparing two
or more independent samples of equal or different sam­
ple sizes. Continuous data were compared using Mann­
Whitney U test when data distribution was not normal and
one­way analysis of variancewhen distributionwas normal.
Odd ratios with 95% confidence intervals (CIs) for predict­
ing morbidity were calculated for several prognostic fac­
tors by using a binary logistic regression analysis, choos­
ing a forward stepping model procedure. Survival analy­
sis was done with the Kaplan­Meier method, compared by
the long­rank and Breslow statistical method. Univariate
and multivariate Cox proportional hazard ratio (HR) anal­
ysis were performed to identify potential prognostic fac­
tors choosing a forward stepping model procedure. Cut­off
points for some continuous variable were evaluated by the
receiver­operating characteristics curve (ROC) as well as
for the performance of prediction model.
Once univariate analysis was completed, we performed
a multivariate forward stepwise logistic regression analysis
(MLR) that included as independent variables only those
variables that were found to be statistically significant in the
univariate analysis. This analysis allowed us to identify ac­
tual independent predictors for optimal surgical candidates
and to establish their individual importance by the calcu­
lation of their respective odds ratios with 95% CIs. The
Hosmer­Lemeshow test was used to assess the goodness­
to­fit.
A p value of less than 0.05 was considered statistically
significant for all tests. Neither CIs nor p value are shown
in the text when results are in tables.
Results
General Characteristics
Out of the 71 patients analyzed, 37 (52%) women were
treated with surgery followed by adjuvant CT and 34 (48%)
women were treated with CT alone.General characteristics
of the patients are shown in Table 1. Overall, most patients
had a platinum treatment­free interval (TFIp) > 12 months
(73%), most women had high­grade serous tumor, and most
were ASA 1­2 and ECOG 0­1. Patients who underwent
SCS were younger and had no residual disease at primary
surgery more frequently.
Table 2 shows the recurrence characteristics in these
series. Most recurrence locations were peritoneal (51%)
or mixed (23%). Women who underwent SCS had
oligometastatic recurrence and less mixed recurrence com­
pared to CT alone.
Most SCS procedures were approached by laparotomy
(60 patients, 84%) and half of them were preceded by la­
paroscopy. In most cases, complete resection was achieved
(33 patients, 89%) after SCS. In two cases (5.5%) residual
disease < 10mm and in another two cases residual disease
> 10 mm was left. Surgical treatment included a wide va­
riety of procedures (Table 3).
Chemotherapy only was more likely delivered in cases
of mixed recurrence (OR: 4.5, 95%CI: 0.9­22; p = 0.07)
or multiple peritoneal metastases (OR: 21, 95%CI: 7­70; p
= 0.001). The regimen most frequently administered was
a platinum­based combination (paclitaxel or doxorubicin)
followed by doxorubicin combined with gemcitabine (Ta­
ble 1). Bevacizumab was more frequently delivered to
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Table 4. — Overall survival (OS) and progression free survival (PFS) Cox regression analysis
for the whole series (n = 71) (expressed as HR with 95%CI)
Univariate OS p PFS p
ASA > 3 3.1 (1.1­9.0) 0.03 3.7 (1.7­7.2) 0.003
Age > 65 years 2.3 (1.2­4.5) 0.003 1.9 (1.0­3.0) 0.024
TFIp 3.0 (1.5­5.9) 0.002 2.5 (1.2­5.3) 0.012
Metastasis
Oligo (≤ 4) 4.7 (1.7­13.0) 0.003 4.1 (1.5­10.0) 0.005
Multiple 7.4 (2.8­16.0) 0.001 6.3 (2.7­14.0) 0.001
Mixed 2.0 (1.0­3.9) 0.023 1.9 (1.0­3.4) 0.032
BV 1.7 (0.9­3.2) 0.106 2.0 (1.1­3.6) 0.021
Multivariate
TFIp 5.5 (2.7­11.3) 0.001 5.8 (2.5­13.3) 0.001
Multiple Metastases 6.2 (2.8­13.5) 0.001 3.8 (1.9­7.3) 0.001
ASA >3 ­ ­ 7.5 (3.0­16.0) 0.001
Mixed recurrence ­ ­ 3.1 (1.5­6.5) 0.002
BV: bevacizumab
women who received only CT than to the SCS group, as
well as those with multiple metastases (54% vs. 27%; p =
0.03) (OR: 3.0, 95%CI: 1.2­8.2).
Survival analysis
At a median follow­up of 51.2 months (IQR: 72.0), me­
dian OS and PFS for the whole series were 68.2 and 21.6
months, respectively.
The probability of survival was better for patients se­
lected for SCS than those who recived CT only (HR: 0.33,
95%CI: 0.17­0.6; p = 0.001). The median OS of the SCS
patients has not been reached at the time of this analysis.
There was also a benefit of disease progression (HR: 0.28,
95%CI: 0.15­0.5; p = 0.001) in surgically treated patients
(Figure 1).
In multivariate analysis, for the whole series, TFIp and
multiple metastases were the most important independent
prognostic factors for survival and recurrence. Performance
status and a mixed recurrence pattern were also significant
for risk of recurrence (Table 4). Quite similar results were
observed in a specific analysis of the SCS+CT group (Ta­
ble 5). Ascites and CA­125 were not included due to their
association with multiple implants.
The use of BV did not significantly impact either OS or
PFS in both SCS+CT and CT groups.
In order to evaluate the actual performance of our selec­
tion criteria (ECOG< 2 or ASA<3, TFIp> 6 months and
number of sites with metastasis) for prediction of whether
the patient is an adequate candidate for SCS, a regression
analysis was made using these factors. Only the number
of sites with metastasis was statistically significant (OR:
30.0).When this analysis was extended by including other
factors known to be related with complete cytoreduction
and previously mentioned, we observed that patient’s age,
residual disease at first surgery, CA­125, mixed recurrence,
and number of metastasis were statistically significant in
univariate analysis. In multivariate, residual disease at first
surgery and number of metastasis were associated with ad­
equate selection of patients to undergo SCS (HR: 5.9 and
30.0, respectively) (Table 6).
Morbidity
Intraoperative complications occurred in five patients
(13.5%), with six intraoperative injuries [bladder injury (n
= 2), liver injury (n = 1), spleen injury (n = 1), colon injury
(n = 1), and vascular injury (n = 1)].
Postoperative morbidity according to Clavien­Dindo
score was very low. Only 5.4% of the patients developed
a severe complication (Clavien­Dindo score ≥ 3). Most
frequent complication was paralytic ileus (7.0%) followed
by infections (8.1%) and moderate­severe pleural effusion
(8.1%). Only one patient required a return to the operating
room (relaparotomy) due to abdominal bleeding.
Mean hospital stay was 8.6 days (range 1­27) and inten­
sive care unit stay was 0.32 days (range 0­2). Mean total
units of blood transfused 1.1 (range 0­8). There was no 90­
day mortality.
Discussion
This study found that complete resection after SCS was
achieved in 89.2% of our patients, most probably due to
a highly selected population. Platinum free­time interval,
and multiple metastases were prognostic factors for risk of
death and recurrence. According to published literatureme­
dian survival after SCS is of 45­61 months (18) and in our
series it has not been reached at the time of this analysis.
Median time to progression was more than two years longer
for patients selected for SCS compared to those treated with
CT only. Since selection to undergo SCS or CT only was
not random, we cannot conclude that the better outcome ex­
perienced by the patients who underwent SCS is due to the
surgery and not due to the factors that made them candidates
to undergo surgery.
Few studies have directly compared the outcomes of
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Table 5. — Overall survival (OS) and progression free survival (PFS) Cox regression analysis
for the surgery group (n = 37) (expressed as HR with 95%CI)
Univariate OS p PFS p
ASA > 3 3.4 (1.1­10.0) 0.03 1.9 (0.7­5.2) 0.2
Age > 65y 2.0 (0.7­5.4) 0.17 7.7 (2.3­25) 0.001
TFIp < 12 m 3.2 (1.0­9.0) 0.03 1.9 (0.7­5.5) 0.21
Metastasis
Oligo (≤ 4) 3.9 (1.5­13.0) 0.02 3.4 (1.1­10.0) 0.026
Multiple 9.4 (2.4­433.0) 0.001 9.5 (2.8­31) 0
Mixed 0.8 (0.23­2.8) 0.759 1.2 (0.3­5.7) 0.736
BV 0.3 (0.2­0.9) 0.03 0.3 (0.1­0.8) 0.02
Multivariate
TFIp < 12 m 9.2 (2.5­26.0) 0.001 6.0 (1.8­17) 0.003
Multiple metastases 10.0 (2.6­30.1) 0.001 5.7 (1.2­26) 0.026
ASA > 3 ­ ­ 4.1 (0.9­20) 0.075
Table 6. — Factors associated with succesful SCS
Parameter Univariate Β coefficient Odds Ratio (OR) (95%CI) p value
RD 1st surgery 0.563 4.6 (1.5­13.8) 0.007
Oligometastatic 3.401 29.0 (8.2­60.0) 0.001
Log CA­125 1.512 4.7 (1.6­14.1) 0.005
Age < 70 0.81 2.3 (1.12­17.5) 0.032
Mixed recurrence 1.52 4.6 (1.5­13.8) 0.007
Multivariate
Oligometastatic (≤ 4) 3.4 30.0 (8.2­108.0) 0.001
RD 1st surgery 1.743 5.9 (1.2­28.0) 0.025
Hosmer­Lemeshow test, p = 0.150, RD, residual disease
platinum­sensitive REOC patients who underwent SCS to
those treated with chemotherapy only [15­18]. Oksef­
jell et al. found that median OS was significantly better
for patients who achieved complete resection compared to
chemotherapy only (54 vs. 13.2 months, respectively), and
localized tumor was the only significant predictive factor
for complete cytoreduction [15]. Szczesny et al reported
a similar study but all patients had complete cytoreduc­
tion surgery [17]. They found that complete resection plus
platinum­based CT improved PFS and OS compared to CT
only, and that complete resection was the single factor that
explained that outcome. In addition, long treatment­free in­
terval, and isolated lesions (≤ 3) could be useful predictors
for complete resection [17]. Gockley et al. reported a retro­
spective analysis of 632 patients who underwent SCS plus
CT or CT only [18]. Cases with complete resection at SCS
had a significant decreased risk of death (HR: 0.38, 95% CI
0.23­0.64). Although they did not directly,analyzed the out­
come according to extent of disease, a better survival after
SCS could be explained because of patients who received
CT alonemore frequently hadmultifocal recurrences or car­
cinomatosis.
DESKTOP III compared SCS plus adjuvant CT versus
CT alone with platinum­based regimens in platinum sensi­
tive REOC with AGO­positive score. A significant benefit
of more than 12 months on OS in complete resection pa­
tients over CT alone was observed [19]. In GOG 213 study,
treatment consisted of carboplatin and paclitaxel alone or
in combination with bevacizumab (BV) followed by BV
maintenance therapy. Patients who were considered appro­
priate for SCS were randomized to surgery followed by CT
versus CT alone [20]. Despite complete resection in 67%
of patients, neither OS nor PFS were improved by SCS.
Our findings, although from a retrospective and small se­
ries of patients, agree with other retrospective studies that
have compared the same treatment modalities and that sup­
port a better outcome in localized recurrence when com­
plete SCS is achieved [15­18, 23, 24]. However, there is
a concern about selection bias. This fact might explain the
superiority of SCS and results must be interpreted with cau­
tion. DESKTOP III results emphasize that complete cytore­
duction is the key to significantly improve survival [19].
Assuming the fact that the more lesions the higher the risk
of an incomplete resection, the number of lesions should
have an impact on the complete resection rate.
Ovarian Cancer Consensus Conference current recom­
mendations to consider a patient as a candidate for SCS
are as follows: TFIp of > 6 months, positive AGO score,
absence of probably unresectable lesions on imaging and
absence of contraindications to surgery [25]. Many retro­
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spective studies have been published that support the sig­
nificance of these factors and, therefore, several models for
predicting complete cytoreduction in SCS and/or survival
have been developed [8­14]. Variables included did not
differ much among studies. They were performance sta­
tus, ascites, residual disease after primary surgery, extent
of disease, progression­free interval, CA­125, FIGO stage
[8­14]. Roughly, these models showed high positive pre­
dictive values (74­89%) for complete resection, but also a
high rate of false negatives (42­71%) [13­14]. According to
our findings, most patients who underwent SCS had a com­
plete resection and prolonged survival. Therefore, we ana­
lyzed the value of our selection criteria for SCS and tried to
identify the optimal patient profile that will allow us to se­
lect the best candidates for SCS. No residual disease at first
surgery and oligometastatic disease had good performance,
with oligometastatic disease, being the most significant fac­
tor. As mentioned by other authors cited above, factors like
TFIp or PFI and good PS are also considered in the decision
making process for whether or not to perform SCS.
The chemotherapy regimens administered to our patients
are similar to the ones used in several other studies [1, 2] and
consisted of platinum­based combination in 74% and dox­
orubicin based combination in 25 % of patients. No spe­
cific CT regimen influenced survival. Bevacizumab was
administered to 40% of patients, more frequently to pa­
tients who did not undergo SCS (CT alone) and in patients
with multiple metastases.Several randomized clinical trials
have tested the efficacy of BV in combination with either
gemcitabine plus carboplatin [26] or carboplatin plus pa­
clitaxel [20] in platinum­sensitive REOC. The OCEANS
study found that PFS for the BV arm was superior to that
of the placebo arm, but no such benefit was found for OS
(26). GOG 213 study found that PFS was also significantly
longer with the addition of bevacizumab to CT compared
to CT alone and in patients with complete resection versus
those who underwent no surgery [20], but found a nega­
tive effect of SCS despite a 67% rate of complete resection
[21]. Since all patients in GOG 213 were eligible to receive
chemotherapy with or without BV, and more than 80% re­
ceived BV, it is difficult to prove if the effect of BV may
have reduced a potential survival benefit associated with
SCS. According to our results, the addition of BV to surgery
seems not to significantly influence either survival or PFS.
Severe post­operative morbidity was low, with a similar
rate to that reported in the published literature. This fact
supports that SCS in REOC does not seem to be more chal­
lenging than primary surgery, when performed by a special­
ized and multi ­disciplinary team [7, 15­17, 27].
Our study has several limitations such as retrospective
design and a small and highly selected series. Its strength
lies in a highly specialized team and experienced center,
and that results of a survival benefit in adequately selected
patients for SCS and agree with the published retrospective
series and the prospective DESKTOP III study.
Conclusion
In conclusion, patients with first REOC and a platinum­
free interval > 6 months managed in a specialized and ex­
perienced center should be evaluated for their eligibility to
undergo SCS. No residual disease after first surgery and
oligometastatic disease at recurrence can be considered as
good predictors for successful SCS with a high expectancy
of complete resection.
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